Adalimumab-Ryvk
2 NDCs across 1 manufacturer|0 Generic,2 Brand
Adalimumab-Ryvk is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
In 2024, Medicare Part D spent $574K on Adalimumab-Ryvk across 440 claims for 159 beneficiaries.
Adalimumab-Ryvk is available as 2 NDCs from 1 manufacturer (0 generic, 2 brand), with NADAC prices from $499.12 to $499.12 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
0G / 2B
Manufacturers
1
competing in market
Price Spread
$499.12 – $499.12
per EA
7d Activity
avg +1.1% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Teva Pharmaceuticals USA Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
1 manufacturer producing ADALIMUMAB-RYVK
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR | $499.1194 per EA | +1.11% |
SIMLANDI(CF) 40 MG/0.4 ML AUTOINJECTOR | $499.1194 per EA | +1.11% |
Frequently Asked Questions
What is Adalimumab-Ryvk used to treat?
Adalimumab-Ryvk is used to treat juvenile arthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, crohn disease and hidradenitis suppurativa, per the National Library of Medicine's MED-RT classification.
How much does Medicare spend on Adalimumab-Ryvk?
In 2024, Medicare Part D spent $574K on Adalimumab-Ryvk across 440 claims for 159 beneficiaries.
How many Adalimumab-Ryvk products are on the market?
The Adalimumab-Ryvk drug market contains 2 NDCs from 1 manufacturer — 0 generic and 2 brand products.
What is the price range for Adalimumab-Ryvk?
NADAC reference prices for Adalimumab-Ryvk range from $499.1194 to $499.1194 per EA.
Which manufacturers make Adalimumab-Ryvk?
1 manufacturer lists Adalimumab-Ryvk in NADAC. Ranked by number of NDCs, the largest are Teva Pharmaceuticals USA Inc. (2).
How has the price of Adalimumab-Ryvk changed recently?
Over the past 7 days, 2 Adalimumab-Ryvk NDCs rose and 0 fell, with a market-wide average change of +1.1%.